Lexaria Bioscience is a biotechnology company that develops and licenses DehydraTECH, a patented drug delivery technology designed to improve how the body absorbs active pharmaceutical ingredients through oral ingestion. The company operates as a platform technology licensing business, using its subsidiary entities to grant exclusive and non-exclusive licenses to pharmaceutical companies, nutraceutical manufacturers, and consumer goods producers seeking to enhance the bioavailability and tolerability of their products, which range from diabetes and weight-loss medications to cannabinoid products and nicotine alternatives. Lexaria generates revenue through licensing agreements and royalty arrangements with its licensees, combining upfront and periodic minimum payments with percentage-of-sales royalties on products incorporating the DehydraTECH technology.